[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553458":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":15,"responsibleParty":32,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Fujian Medical University Union Hospital","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":13,"email":14},"Huifang Huang","CONTACT","13365910318","0591-86218641","huanghuif@fjmu.edu.cn",[16],{"facility":5,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"RECRUITING","Fuzhou","Fujian","350001","China","CN",{"type":24,"coordinates":25},"Point",[26,27],119.30611,26.06139,{"lat":27,"lon":26},[30],{"name":31,"role":11,"phone":12,"phoneExt":13,"email":14},"huifang huang",{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Huifang Huang, MD","Professor","100553458","il-6-a-marker-for-aml-chemo-sensitivity-100553458",false,"NCT06486350","IL-6: A Marker for AML Chemo Sensitivity","Bone Marrow Supernatant IL-6 as a Predictor of Chemotherapy Sensitivity in AML Patients","Inclusion Criteria:\n\n1. Clinical diagnosis aligns with the \"Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)\";\n2. All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study;\n3. Patients participate in the study accompanied by family members and sign informed consent documents.\n\nExclusion Criteria:\n\n1. Patients with concurrent malignancies requiring treatment;\n2. Presence of infectious diseases, including SARS, viral hepatitis, or HIV\u002FAIDS;\n3. Major surgery performed within the last 21 days;\n4. Performance Status (PS) score \\>3;\n5. Severe liver or kidney dysfunction or serious infection;\n6. Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.","ALL","18 Years",{"count":46,"type":47},72,"ESTIMATED","OBSERVATIONAL","Acute myeloid leukemia (AML) is a clonal malignancy that arises from the primitive hematopoietic cells within the hematopoietic system. According to SEER cancer statistics, the 5-year survival rate for AML patients stands at a concerning 30%. Despite therapeutic advancements, the development of chemotherapy resistance and the risk of disease relapse pose significant barriers to curative outcomes. Evidence has linked elevated interleukin-6 (IL-6) levels in plasma and bone marrow to a poorer prognosis in AML, with IL-6 potentially fostering chemotherapy resistance through the enhancement of fatty acid uptake and the induction of stromal-like morphological changes in AML cells. However, the role of IL-6 as a potential biomarker for monitoring chemotherapy sensitivity in AML has not been fully elucidated. This study seeks to investigate the correlation between IL-6 levels in bone marrow supernatant and the sensitivity to chemotherapy, offering a clinical perspective that could pave the way for improved prognostic markers and personalized treatment strategies.",[51],"AML, Adult",[53,54,55],"AML","IL-6","Chemotherapy sensitivity","2024-06-30",{"date":58,"type":59},"2024-07-03","ACTUAL",{"date":61,"type":59},"2023-10-01",{"date":63,"type":47},"2025-06",{"name":5,"class":6},1]